Gene test could make chemo safer by tailoring doses

NCT ID NCT07158164

Recruiting now Disease control Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adjusting the dose of chemotherapy drugs (fluorouracil or capecitabine) based on a person's DPYD gene test can lower the risk of severe side effects. About 100 cancer patients with a specific gene variant will receive either a reduced starting dose or standard dose. The goal is to find a safer, more personalized way to give chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fluorouracil or Capecitabine (chemotherapy drugs)
What this could lead to: If successful, this could make chemotherapy safer by using a genetic test to personalize doses, reducing severe side effects without lowering effectiveness.
What could go wrong: This is a small, early-phase study (100 people) and results may not apply to all patients. The genetic test is not yet standard, and dose adjustments might still lead to side effects or reduced cancer control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm colorectal neoplasm head and neck neoplasm Head and Neck Neoplasms small intestinal intraepithelial neoplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS COLORECTAL NEOPLASMS GASTRO-INTESTINAL INTRAEPITHELIAL NEOPLASIA HEAD AND NECK NEOPLASMS

Contacts and locations

Locations

Cancer Center Initiative
RECRUITING

Newark, New Jersey, 07103, United States
Cooperman Barnabas Medical Center
RECRUITING

Livingston, New Jersey, 07039, United States
Jack and Sheryl Morris Cancer Center
RECRUITING

New Brunswick, New Jersey, 08901, United States
RWJBarnabas Health - Community Medical Center
RECRUITING

Toms River, New Jersey, 08755, United States
RWJBarnabas Health - Robert Wood Johnson University Hospita
RECRUITING

New Brunswick, New Jersey, 08903, United States
RWJBarnabas Health - Robert Wood Johnson University Hospital Somerset
RECRUITING

Somerville, New Jersey, 08873, United States
RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton
RECRUITING

Hamilton, New Jersey, 08690, United States
RWJBarnabas Health Clara Maas Medical Center
RECRUITING

Belleville, New Jersey, 07109, United States
RWJBarnabas Health Jersey City Medical Center
RECRUITING

Jersey City, New Jersey, 07302, United States
RWJBarnabas Health Newark Beth Israel Medical Center
RECRUITING

Newark, New Jersey, 07112, United States
Trinitas Hospital and Comprehensive Cancer Center
RECRUITING

Elizabeth, New Jersey, 07202, United States
University Hospital
RECRUITING

Newark, New Jersey, 07103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.